



## MANITOBA RENAL PROGRAM

|  |   |
|--|---|
| <b>SUBJECT</b><br><ul style="list-style-type: none"> <li>Screening for Hepatitis B, Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA), and Carbapenemase-Producing <i>Enterobacteriaceae</i> (CPE) for Manitoba Renal Program Travelling Patients and Transient Hemodialysis Patients</li> </ul> | <b>SECTION</b> 70.20 Hemodialysis Protocols       |
|  | <b>CODE</b> 70.20.03                              |
| <b>AUTHORIZATION</b><br><ul style="list-style-type: none"> <li>Professional Advisory Committee, Manitoba Renal Program</li> <li>Nursing Practice Council, St. Boniface Hospital</li> </ul>   | <b>EFFECTIVE DATE</b> June 1984                   |
|  | <b>REVISION DATE</b> September 2013<br>April 2018 |

### PURPOSE:

- To reduce the risk of healthcare associated transmission of antibiotic resistant organisms Methicillin Resistant *Staphylococcus aureus* (MRSA) and Carbapenemase-Producing *Enterobacteriaceae* (CPE).
- Timely identification of MRSA and CPE positive patients receiving hemodialysis (HD) treatment in Manitoba after receiving HD treatment and/or hospitalization outside the province while minimizing resource utilization.

### DEFINITIONS:

- Manitoba Renal Program (MRP) Travelling Patients:** HD patients who receive chronic HD treatments through the MRP and returning to Manitoba after receiving HD and/or being hospitalized outside of the Province of Manitoba.
- Transient Hemodialysis Patients:** Hemodialysis patients from outside the Province of Manitoba who require HD treatment in Manitoba.

### POLICY:

- Requests for transient HD treatment in Manitoba from outside the province should be forwarded to the Manitoba Renal Program to ensure proper diagnostic screening of patients traveling to Manitoba occurs prior to their arrival.
- When MRP patients return from traveling out of province, the receiving hemodialysis unit must ensure proper diagnostic screening of the travelling patients occurs.
- The CRN or delegate shall contact their facility Infection Control Professional **prior** to a MRP Travelling Patient returning for HD treatment in an MRP dialysis unit after receiving HD treatment outside of Manitoba. The Infection Control Professional shall determine if CPE screening is necessary. Transient Hemodialysis Patients must be screened for CPE **prior** to arriving in Manitoba for treatment.

**Note: As test for CPE may require special lab approval, it is recommended that the MRP unit contact the lab once patient's travel plans are known.**

### PROTOCOL:

1. Once dates and space have been allocated, a letter outlining the diagnostic screening and patient information required for the out of province transient patient will be sent to the sending dialysis unit. (70.20.03b Appendix B).
2. Once MRP patients have been allocated dates and space in a receiving unit, diagnostic screening and patient information will be sent as requested by the receiving unit

**A. Out of Province Transient HD Patients Receiving Dialysis in Manitoba:**

1. Transient patients who are HBsAg positive will not be electively accepted for treatment in the Manitoba Renal Program unless prior arrangements for an isolation room have been made.
2. The transient patients Hepatitis B (i.e. HBsAg) results taken within the **last month (1 month)** must be received by the MRP receiving dialysis unit prior to the scheduled dialysis treatment.  
NOTE: Unauthorized transient patients, without known Hepatitis status must be assessed and if dialysis is required they will be dialyzed in a private room on Contact Precautions.
3. The transient patient's MRSA and CPE results taken 1 week prior to the scheduled dialysis treatment must be received by the MRP receiving dialysis unit in advance. The results should include a list of antibiotics the patient has received 48 hours prior to culture. Patients with unknown results or who are MRSA or CPE positive will be considered for transient dialysis, but they must be placed on Additional Precautions. Additional Precautions for CPE must be strictly maintained.

***The following swabs must be done within 1 week prior to the scheduled transient dialysis treatment:***

**MRSA**

- Right and left anterior nares (one for both nares)
- All open wounds/lesions/incisions/invasive device insertion sites (e.g., central venous access device). Do not collect specimens from closed wounds/ lesions/incisions/ invasive device insertion sites,

**CPE**

- Rectum (or if colostomy or ileostomy, culture stoma site). Peri-rectal swabs, instead of rectal swabs may be submitted for patients with neutrophils below  $1.0 \times 10^9/L$  for greater than 7 to 10 days or patients currently/recently undergoing a hematopoietic stem cell transplant procedure. A rectal swab is required for patients who do not meet these criteria.

***NOTE: do not repeat screening of known CPE Positive patients***

**DO NOT routinely screen for:**

- Vancomycin Resistant Enterococci (VRE)
- Extended Spectrum Beta Lactamase Producing Microorganisms (ESBLs)
- Other Antimicrobial Resistant Gram Negative Bacilli (AMR GNB)

**B. Manitoba Renal Program Patients Receiving Transient Dialysis Outside the Province:**

1. Out of province renal programs have their own requirements for screening transient dialysis patients prior to travel. Patients will be screened as requested and the diagnostic results and the patient information will be sent to the receiving unit.
2. MRP patients who are Hepatitis B susceptible (i.e. HbsAb negative), will be screened for HBsAg upon return to their unit.
3. Once MRP transient dialysis patients return from out of province, they must be swabbed for MRSA and for CPE as outlined in policy statement #3 above. The patients shall be dialyzed using Additional Precautions, per facility/regional policy, until negative screening results are received. Note: once positive with CPE, the patient is always considered positive (i.e., do not repeat screening of CPE

Positive patients).

**REFERENCES:**

Centers for Disease Control and Prevention. (2001, April 27). *Recommendations for preventing transmission of infections among chronic hemodialysis patients*. Retrieved 2009-05-22, from <http://www.cdc.gov/mmwr/PDF/RR/RR5005.pdf>

Dialysis Infection Prevention and Control Working Group, WRHA and Manitoba Health, January 2018.

MHSAL ARO Guidelines 2016: <https://www.gov.mb.ca/health/publichealth/cdc/docs/ipc/aro.pdf>

Winnipeg Regional Health Authority (revised July 2016). *Acute Care Infection Prevention & Control Manual*. Retrieved 10-Jan-2018 from [http://www.wrha.mb.ca/extranet/ipc/files/manuals/acutecare/ManualHospital\\_Full.pdf](http://www.wrha.mb.ca/extranet/ipc/files/manuals/acutecare/ManualHospital_Full.pdf)